221385-22-4

Upstream product

• 95-92-1 oxalic acid diethyl ester 
• 93-55-0 1-phenyl-propan-1-one 

Downstream Products

• 1609483-05-7 ethyl 4-methyl-5-phenyl-1-(4-phenylthiazol-2-yl)-1H-pyrazole-3-carboxylate 
• 1609483-21-7 ethyl 4-methyl-1-(5-methyl-4-phenylthiazol-2-yl)-5-phenyl-1H-pyrazole-3-carboxylate 
• 158941-07-2 1-(2,4-Dichlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid 
• 221385-47-3 1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxylic acid 
• 158941-08-3 1-(2,4-Dichlorophenyl)-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid chloride 
• 112009-32-2 4-methyl-1,5-diphenyl-1H-pyrazole-3-carboxylic acid 
• 221385-48-4 1-(2,4-dichloro-phenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carbonyl chloride 
• 221385-23-5 1-(2,4-dichlorophenyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 741286-97-5 4-methyl-5-phenyl-1-(3-pyridyl)pyrazole-3-carboxylic acid ethyl ester 
• 950816-46-3 1-(5-chloropentyl)-4-methyl-5-phenyl-1H-pyrazole-3-carboxylic acid ethyl ester 
• 501426-48-8 1-(2,4-dichlorophenyl)-4-methyl-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

An efficient one-pot synthesis of aryl-substituted 1-(thiazol-2-yl)-1H- pyrazole-3-carboxylates via a hantzsch synthesis-knorr reaction sequence

The treatment of α-bromoalkyl aryl ketones and 2-(propan-2-ylidene) hydrazine carbothioamide afforded 4-aryl-2-(2-(propan-2-ylidene)hydrazinyl) thiazoles via a Hantzsch-thiazole synthesis, which reacted with 4-aryl-2,4-diketoesters via a sequential Knorr-

1,5-Diarylpyrazole and vanillin hybrids: Synthesis, biological activity and DFT studies

Herein, we report the design and synthesis of 13 diarylpyrazole hybrids with vanillin constructed as dual compounds against oxidative stress and diabetes. Compounds were tested in two different antioxidant assays. It was found that all compounds showed an

Discovery of rimonabant and its potential analogues as anti-TB drug candidates

Rimonabant and its analogues have been synthesized in moderate to good yields using a simple synthetic route. All the newly synthesized compounds were subjected to in vitro screening against M. tuberculosis and M. smegmatis. The most potent analogue JMG-14 exhibits MIC value of 3.13 compared to 3.25 and 50 μ/ml for ethambutol and pyrazinamide, respectively. The molecular docking reveals that pyrazole ring, number and position of halogen atoms play a crucial role in deciding interactions with MTCYP-121. These findings open up a new avenue in the search of potent anti-TB drugs with rimonabant and its novel analogue JMG-14 as lead molecules.

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

THERAPEUTIC AGENTS

The present invention relates to a 1,5-diphenylpyrazole compound and its use in the treatment of obesity, psychiatric and neurological disorders, to methods for the its therapeutic use and to pharmaceutical compositions containing them.

PYRAZOLE DERIVATIVE

Not available

PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS

Novel cannabimimetic pyrazole derivatives are presented which have preferentially high affinities for both of the cannabinoid CB1 or CB2 receptor sites. The improved receptor affinity makes these analogs useful as experimental tools for cannabinoid receptor studies as well as clinically useful agents in individuals and animals for treatment of memory deficits associated with aging or neurological diseases, as anti-obesity agents, as medications for schizophrenia and treatment of septic shock syndrome.